Dr. Robert W. Hagar, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 38
Licensed in California since 1984, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Virginia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license G53126 (first issued 1984; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Alta Bates Summit Medical Center - Alta Bates Camp Berkeley, CA
- UCSF Benioff Children's Hospital Oakland Oakland, CA
Medical groups
- UCSF Medical Group Business Services (1,598 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 38
- Services billed
- 310
- Patients’ average age
- 47
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 133 | 30 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Oakland, CA | 26 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Oakland, CA | 23 |
| Hydromorphone Hcl Other prescribers in Oakland, CA | 20 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Oakland, CA | 15 |
| Promethazine Hcl Other prescribers in Oakland, CA | 12 |
| Methadone Hcl Other prescribers in Oakland, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $12,848 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $12,347 |
|---|---|
| Chiesi USA, Inc. | $160 |
| Agios Pharmaceuticals, Inc. | $141 |
| Novo Nordisk Inc | $125 |
| Pfizer Inc. | $76.49 |
| Consulting Fee | $10,983 |
|---|---|
| Travel and Lodging | $1,282 |
| Food and Beverage | $584 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee | $10,983 |
| Vertex Pharmaceuticals Incorporated Jul 27, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $765 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $93.75 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $75.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $38,170 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Agios Pharmaceuticals, Inc. - A randomized doubleblind placebocontrolled multicenter study to assess the safety and efficacy of inclacumab in participants with sickle cell disease experiencing vasoocclusive crises
Global Blood Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.